VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Sieber on the CHAARTED Trial

Paul R. Sieber, MD
Published: Thursday, Jan 08, 2015


Paul Sieber, MD, principal investigator for clinical trials with Lancaster Urology, talks about the CHAARTED trial, which examines chemohormonal therapy versus androgen ablation for extensive disease in prostate cancer.

The study looked at patients that have received no previous treatment., Siebar says. During the trial, half the patients received standard hormonal therapy while the other half received standard hormonal therapy plus 6 cycles of docetaxel. Sieber says patients with both high-volume metastasis and low-volume disease were included in the study.

Findings over a period of years showed the survival advantage was about 17 months in the group that had high-volume metastatic disease. These results could change how patients with metastatic disease are treated initially, says Sieber. However, there is some controversy surrounding CHAARTED because the data is limited and similar studies have had differing findings.

Paul Sieber, MD, principal investigator for clinical trials with Lancaster Urology, talks about the CHAARTED trial, which examines chemohormonal therapy versus androgen ablation for extensive disease in prostate cancer.

The study looked at patients that have received no previous treatment., Siebar says. During the trial, half the patients received standard hormonal therapy while the other half received standard hormonal therapy plus 6 cycles of docetaxel. Sieber says patients with both high-volume metastasis and low-volume disease were included in the study.

Findings over a period of years showed the survival advantage was about 17 months in the group that had high-volume metastatic disease. These results could change how patients with metastatic disease are treated initially, says Sieber. However, there is some controversy surrounding CHAARTED because the data is limited and similar studies have had differing findings.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x